Management of Residual Psoriasis in Patients on Biologic Treatment

2020 ◽  
Vol 19 (2) ◽  
pp. 188-194
Author(s):  
Wasim Haidari ◽  
Adrian Pona ◽  
Steven Feldman
Keyword(s):  
Biologic Treatment

The Psoriasis Patient Journey: Progression from Topical to Biologic Treatment for Psoriasis Patients in the United States

2018 ◽  
Vol 2 ◽  
pp. S13
Author(s):  
Jashin J Wu ◽  
Minyi Lu ◽  
Karen A Veverka ◽  
Maartje Smulders ◽  
Eros Papademetriou ◽  
...  
Keyword(s):  
United States ◽  
Psoriasis Patient ◽  
The United States ◽  
Biologic Treatment ◽  
Patient Journey

Abstract not available. Disclosures: Study sponssored by LEO Pharma. Copyright 2018 SKIN

scholarly journals Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic

2020 ◽  
pp. flgastro-2020-101563
Author(s):  
Stephanie Shields ◽  
Allan Dunlop ◽  
John Paul Seenan ◽  
Jonathan Macdonald
Keyword(s):  
Clinical Care ◽  
Chronic Illnesses ◽  
Therapeutic Drug ◽  
Disease Monitoring ◽  
Biologic Treatment ◽  
Faecal Calprotectin ◽  
Routine Clinical Care ◽  
Risk Of Disease ◽  
Inflammatory Bowel ◽  
The Impact

COVID-19 has dominated life in 2020 with, at the time of writing, over 4.9M global cases and >320 000 deaths. The impact has been most intensely felt in acute and critical care environments. However, with most UK elective work postponed, laboratory testing of faecal calprotectin halted due to potential risk of viral transmission and non-emergency endoscopies and surgeries cancelled, the secondary impact on chronic illnesses such as inflammatory bowel disease (IBD) is becoming apparent. Data from the Scottish Biologic Therapeutic Drug Monitoring (TDM) service shows a dramatic drop in TDM testing since the pandemic onset. April 2020 saw a 75.6% reduction in adalimumab testing and a 36.2% reduction in infliximab testing when compared with February 2020 data, a reduction coinciding with the widespread cancellation of outpatient and elective activity. It is feared that disruption to normal patterns of care and disease monitoring of biologic patients could increase the risk of disease flare and adverse clinical outcomes. Urgent changes in clinical practice have been instigated to mitigate the effects of the pandemic on routine clinical care. Further transformations are needed to maintain safe, effective, patient-centred IBD care in the future.

scholarly journals Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis

2015 ◽  
pp. 777 ◽  
Author(s):  
Mingliang Zhang ◽  
Susan Brenneman ◽  
Chureen Carter ◽  
Breanna Essoi ◽  
Kamyar Farahi ◽  
...  
Keyword(s):  
Treatment Satisfaction ◽  
Biologic Treatment ◽  
Patient Reported ◽  
Dosing Frequency

Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment

2021 ◽  
Author(s):  
Daniel Sumpton ◽  
Ayano Kelly ◽  
Jonathan C. Craig ◽  
Geraldine Hassett ◽  
Barry Kane ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Discrete Choice Experiment ◽  
Discrete Choice ◽  
Choice Experiment ◽  
Biologic Treatment

Real world evidence on time to relapse of plaque psoriasis after discontinuation of biologic treatment in Poland

2021 ◽  
Author(s):  
Witold Owczarek ◽  
Maciej Dzik ◽  
Joanna Narbutt ◽  
Irena Walecka ◽  
Marta Kowalczyk
Keyword(s):  
Real World ◽  
Plaque Psoriasis ◽  
Biologic Treatment ◽  
Real World Evidence ◽  
Time To Relapse

scholarly journals Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yiting Wang ◽  
Rupa Makadia ◽  
Christopher Knoll ◽  
Jill Hardin ◽  
Erica A. Voss ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Health Care ◽  
Health Care Utilization ◽  
Corticosteroid Treatment ◽  
Biologic Agent ◽  
Care Utilization ◽  
Biologic Treatment ◽  
Patient Journey ◽  
Care Experience ◽  
Oral Corticosteroids

Abstract Background There has been a more pronounced shift toward earlier, more aggressive therapies in Crohn’s disease than in ulcerative colitis (UC). The aim of this study was to describe the pre-biologic treatment and health care experience, including co-morbidities and overall health care utilization, for UC patients who initiated biologic therapies, in the 5 years prior to the initiation of the first biologic agent. Methods UC patients who initiated a biologic agent approved for UC between 9/15/2005 and 1/30/2018 were identified from the IBM® MarketScan® Commercial Database, a large US database. The date of the first recorded UC biologic exposure was defined as the index date, and ≥ 5 years of pre-index records were required to evaluate patients’ treatment, disease progression and overall health care utilization prior to initiating biologic agents. Results Among the 1891 eligible patients, treatment with oral corticosteroids, 5-aminosalicylates, and other non-biologic immunomodulators, all increased progressively across the 5 years prior to the index. From within year-five to within year-one prior to the index, the median duration of oral corticosteroid treatment increased from 34 to 88 days per year and the proportion of patients who experienced more extensive/pancolitis disease increased from 16 to 59%. Overall, the frequency of all-cause health care visits also increased. Conclusions Patients with UC experienced increasing morbidity and treatment burden in the 5 years prior to initiating biologic therapy. To achieve reduced corticosteroids in UC management, better risk stratification is needed to help identify patients for more timely biologic treatment.

Biologic treatment for chronic recurrent multifocal osteomyelitis: report of four cases and review of the literature

2017 ◽  
Vol 38 (1) ◽  
pp. 153-160 ◽  
Author(s):  
Elena Tronconi ◽  
Angela Miniaci ◽  
Michelangelo Baldazzi ◽  
Laura Greco ◽  
Andrea Pession
Keyword(s):  
Chronic Recurrent Multifocal Osteomyelitis ◽  
Review Of The Literature ◽  
Biologic Treatment ◽  
Multifocal Osteomyelitis
Sign in / Sign up

Export Citation Format

Share Document